🔗 Share this article

Given that the United States continues making sweeping revisions to its vaccination recommendations, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by questioning Covid vaccines in the pandemic and has zeroed in on possible deaths following Covid immunization in her brief tenure at the FDA.

Proposed Shifts to Pediatric Vaccine Schedule

Agency leaders had intended to announce sweeping changes to the childhood vaccination calendar recently, aligning the US with Denmark’s vaccine program, according to reports – a major change that would put the US out of step with many the international standard with little proof for improved outcomes. The planned update has been postponed until the coming year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this calendar year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has repeatedly called for ending some pediatric vaccine recommendations in the US to become more in line with Denmark's approach, a society with nationalized medicine and a citizenry about the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on immunizations – traditionally the purview of Dr. Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Questions Over Qualifications

Dr. Høeg has no apparent track record in drug development, oversight or administrative roles, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, remarked Jonathan Howard. “She’s never run a clinical trial. She is not versed in running a sizeable institution. She lacks background in industry regulation.”

Previous commissioners of the center would “be deeply familiar with legal statutes and the underlying principles of medication creation”, noted Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who led the center have had.”

This division has an vast range of responsibilities at the agency, she emphasized.

“Many people just focuses on the novel medication approvals, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and other areas, and all of those need to be looked after,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant management element to the position, which manages over 5,000 staff members. “It’s a massive leadership role, if you execute it properly,” Woodcock concluded.

Response and Controversial Policies

When asked about inquiries about Dr. Høeg's qualifications and whether this appointment signifies more teamwork among regulatory chiefs on immunizations, a press secretary stated that the “inquiries stem from inaccurate assumptions”.

“This background aligns with the responsibilities of her position,” the spokesperson said, citing the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg takes over the commissioner’s controversial expedited review system, a disputed one-day medication authorization process that reportedly concerned her former heads. “How are these therapies being selected for this voucher program? Who makes the calls?” Howard questioned. “There is a lot of secrecy happening at the agency right now.”

Overall, he stated, “the FDA appears to be shifting towards laxer oversight of pharmaceuticals, except for shots.”

Established History on Immunizations

With vaccines, Høeg has a clearer, if concerning, past, critics observe. She authored a analysis using unconfirmed volunteer-provided data to assess the frequency of heart inflammation after COVID-19 vaccination. She consulted for the Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the current government included revising regulations for new vaccines and ending “non-essential” vaccines, she said post-election on a online show. At the FDA, Høeg has allegedly proposed preventing young men from getting COVID-19 vaccinations.

“She’s an complete true believer who commences with her beliefs and tailors the evidence to accommodate the science in a extremely deceptive, fraudulent way,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|